OCTAPHARMA

Serial Number 76314715
Registration 2938519
800

Registration Progress

Application Filed
Sep 20, 2001
Under Examination
Dec 3, 2002
Approved for Publication
Aug 21, 2002
Published for Opposition
Sep 10, 2002
Registered
Apr 5, 2005

Basic Information

Serial Number
76314715
Registration Number
2938519
Filing Date
September 20, 2001
Registration Date
April 5, 2005
Published for Opposition
September 10, 2002
Renewal Date
April 5, 2025
Drawing Code
1

Status Summary

Current Status
Active
Status Code
800
Status Date
Dec 27, 2024
Registration
Registered
Classes
005

Rights Holder

Octapharma AG

03
Address
Seidenstrasse 2
Lachen 8853
CH

Ownership History

Octapharma AG

Original Applicant
03
Lachen CH

Octapharma AG

Owner at Publication
03
Lachen CH

Octapharma AG

Original Registrant
03
Lachen CH

Legal Representation

Attorney
Henry B. Ward, III
USPTO Deadlines
Next Renewal Deadline
Section 8 & 9 (30-Year) Renewal Due (Based on registration date 2005-04-05)
Due: April 05, 2035 (3559 days remaining)
Grace period ends: October 05, 2035

Application History

48 events
Date Code Type Description
Jan 30, 2025 EWOR I TEAS WITHDRAWAL AS DOMESTIC REPRESENTATIVE RECEIVED
Jan 30, 2025 TCCA I TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 30, 2025 ECDR I TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Jan 30, 2025 ARAA I ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Jan 30, 2025 REAP I TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Jan 30, 2025 COAR I TEAS CHANGE OF OWNER ADDRESS RECEIVED
Jan 30, 2025 CHAN I APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Dec 27, 2024 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Dec 27, 2024 RNL2 Q REGISTERED AND RENEWED (SECOND RENEWAL - 10 YRS)
Dec 27, 2024 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Dec 27, 2024 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Sep 13, 2024 E89R I TEAS SECTION 8 & 9 RECEIVED
Apr 5, 2024 REM2 E COURTESY REMINDER - SEC. 8 (10-YR)/SEC. 9 E-MAILED
Apr 9, 2015 NA89 E NOTICE OF ACCEPTANCE OF SEC. 8 & 9 - E-MAILED
Apr 9, 2015 RNL1 Q REGISTERED AND RENEWED (FIRST RENEWAL - 10 YRS)
Apr 9, 2015 89AG O REGISTERED - SEC. 8 (10-YR) ACCEPTED/SEC. 9 GRANTED
Apr 9, 2015 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Mar 26, 2015 E89R I TEAS SECTION 8 & 9 RECEIVED
Apr 12, 2011 C15A O REGISTERED - SEC. 8 (6-YR) ACCEPTED & SEC. 15 ACK.
Apr 12, 2011 APRE A CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Apr 4, 2011 E815 I TEAS SECTION 8 & 15 RECEIVED
Apr 5, 2005 R.PR A REGISTERED-PRINCIPAL REGISTER
Jan 3, 2005 REGV O LAW OFFICE REGISTRATION REVIEW COMPLETED
Dec 30, 2004 ALIE A ASSIGNED TO LIE
Dec 22, 2004 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
Dec 22, 2004 SUPC I STATEMENT OF USE PROCESSING COMPLETE
Dec 22, 2004 EX4G S SOU EXTENSION 4 GRANTED
Dec 3, 2004 IUAF S USE AMENDMENT FILED
Dec 3, 2004 EXT4 S SOU EXTENSION 4 FILED
Dec 3, 2004 MAIL I PAPER RECEIVED
Jun 25, 2004 EX3G S SOU EXTENSION 3 GRANTED
Jun 15, 2004 CFIT O CASE FILE IN TICRS
Jun 3, 2004 EXT3 S SOU EXTENSION 3 FILED
Jun 3, 2004 MAIL I PAPER RECEIVED
Apr 26, 2004 DOCK D ASSIGNED TO EXAMINER
Jan 7, 2004 EX2G S SOU EXTENSION 2 GRANTED
Dec 3, 2003 EXT2 S SOU EXTENSION 2 FILED
Dec 3, 2003 MAIL I PAPER RECEIVED
Jun 26, 2003 EX1G S SOU EXTENSION 1 GRANTED
May 29, 2003 EXT1 S SOU EXTENSION 1 FILED
May 29, 2003 MAIL I PAPER RECEIVED
Dec 3, 2002 NOAM O NOA MAILED - SOU REQUIRED FROM APPLICANT
Sep 10, 2002 PUBO A PUBLISHED FOR OPPOSITION
Aug 21, 2002 NPUB O NOTICE OF PUBLICATION
May 29, 2002 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 18, 2002 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 27, 2001 CNRT F NON-FINAL ACTION MAILED
Nov 20, 2001 DOCK D ASSIGNED TO EXAMINER

Detailed Classifications

Class 005
Pharmaceutical products, namely blood plasma derivatives in the nature of virus inactivated blood plasma, blood clotting factors, immunoglobulins
First Use Anywhere: Jun 30, 2004
First Use in Commerce: Jun 30, 2004

Classification

International Classes
005